Volume 71, Issue 3

Search all Cancer Immunology, Immunotherapy articles

March 2022

21 articles in this issue

Chemotherapy: a double-edged sword in cancer treatment
Nafiseh Behranvand
Farzad Nasri
Reza Falak
Review 05 August 2021 Pages: 507 - 526
Correction to: Chemotherapy: a double‑edged sword in cancer treatment
Nafiseh Behranvand
Farzad Nasri
Reza Falak
Correction 28 August 2021 Pages: 527 - 527
A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma
Anneloes van Duijn
Karin J. Willemsen
Walbert J. Bakker
Original Article Open access 15 July 2021 Pages: 529 - 540
Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer
Elgin Hoffmann
Frank Paulsen
Franziska Eckert
Original Article Open access 16 July 2021 Pages: 541 - 552
Transcriptomic signatures of tumors undergoing T cell attack
Aishwarya Gokuldass
Aimilia Schina
Marco Donia
Original Article 17 July 2021 Pages: 553 - 563
Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma
Tomoya Mizuno
Takao Kamai
Ken-Ichiro Yoshida
Original Article Open access 18 July 2021 Pages: 565 - 578
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
Da Hyun Kang
Chaeuk Chung
Jeong Eun Lee
Original Article Open access 18 July 2021 Pages: 579 - 588
Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma
Masahiro Ohira
Ryuichi Hotta
Hideki Ohdan
Original Article 19 July 2021 Pages: 589 - 599
Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq
Hongkai Zhuang
Xinming Chen
Baohua Hou
Original Article 19 July 2021 Pages: 601 - 612
Part of 1 collection:

Regulatory T cells in cancer immunosuppression
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21
Jaya Lakshmi Thangaraj
Minh-Trang Thi Phan
Je-Jung Lee
Original Article 20 July 2021 Pages: 613 - 625
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody
Tamara Mateu-Albero
Raquel Juárez-Sánchez
Carlos Cuesta-Mateos
Original Article 23 July 2021 Pages: 627 - 636
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
Hui Yu
Ping Chen
Bei Zhang
Original Article 23 July 2021 Pages: 637 - 644
ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas
Houshi Xu
Anke Zhang
Meiqing Lou
Original Article 27 July 2021 Pages: 645 - 660
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection
Xiuxing Chen
Ziming Du
Yuhong Li
Original Article 28 July 2021 Pages: 661 - 674
A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma
Yajing Zhang
Yujie Zhu
Ye Zhang
Original Article 03 August 2021 Pages: 675 - 688
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
Xian Zhang
Junfang Yang
Peihua Lu
Original Article 07 August 2021 Pages: 689 - 703
The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells
Pin-Jui Kung
Ting-Yu Lai
Chih-Yuan Lee
Original Article Open access 10 August 2021 Pages: 705 - 718
Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials
Thierry Landre
Gregoire Justeau
Boris Duchemann
Original Article 10 August 2021 Pages: 719 - 726
Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer
Mizuki Kobayashi
Nobuhiro Fujiyama
Masaki Shiota
Original Article 11 August 2021 Pages: 727 - 736
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Hiroshi Takumida
Hidehito Horinouchi
Yuichiro Ohe
Original Article Open access 14 August 2021 Pages: 737 - 746
An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors
Pu Wu
Wei Sun
Hao Zhang
Original Article 16 August 2021 Pages: 747 - 759

Volume 71, Issue 3

Chemotherapy: a double-edged sword in cancer treatment

Correction to: Chemotherapy: a double‑edged sword in cancer treatment

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer

Transcriptomic signatures of tumors undergoing T cell attack

Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma

Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors

Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma

Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq

Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21

Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas

Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection

A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia

The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells

Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials

Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors

Navigation